Elanco Animal Health Inc ELAN

Elanco Animal Health Inc’s strongest supplied fact is its latest filed quarter: revenue from contracts with customers, excluding assessed tax, was $1.37B in the 10-Q for the period ended 2026-03-31, while net income attributable to parent was $57.0M and diluted EPS was $0.11 on 506.0M diluted shares. That makes today’s file a filing-led equity story rather than a rumour-led market wrap.

Elanco is an animal-health operating business, and the supplied product rail matters because it connects the numbers to real commercial demand. The 10-Q says many products are sold consistently through the year, but pet health has seasonality because demand for certain parasiticide product offerings rises in the first half of the year. The same filing says product sales with one customer produced accounts receivable of $117 million at 2026-03-31 and $107 million at 2025-12-31, a concrete reminder that product flow and cash timing sit behind the share ticker.

The latest SEC financial rail shows $13.22B of assets, $6.72B of liabilities, $6.50B of stockholders' equity attributable to parent and $428.0M of cash and cash equivalents at carrying value, all from the 10-Q period ended 2026-03-31. Operating cash flow was $13.0M, payments to acquire property, plant and equipment were $51.0M, research and development expense was $97.0M and inventory, net, was $1.72B. The supplied prior annual fact adds a $57.0M increase in inventories for the 10-K period ended 2025-12-31.

The supplied source route is an SEC route, not a chart route. The public developments named here are official filings: SEC EDGAR Form 4 filings dated 2026-06-16, SEC EDGAR Form 4 filings dated 2026-06-02, the SEC filing index, the SEC submissions JSON, the SEC companyfacts JSON, the 10-Q filed 2026-05-06 and the 8-K filed 2026-05-06. No price level, trading range, moving average or chart signal is supplied, so none belongs in this report.

The 8-K filed 2026-05-06 says Exhibit 99.1 was a press release announcing results of operations for the fiscal quarter ended 2026-03-31 and guidance for the full year and second quarter of 2026. The evidence pack does not supply the guidance figures themselves, so the honest treatment is to name the filing event without inventing the forecast.

The current tension is simple: the official rail gives a profitable first quarter, a large inventory balance, modest operating cash flow against capital spending, real pet-health seasonality and fresh insider-reporting filings. What it does not give is a live chart route, updated post-quarter sales data, detailed guidance figures, or the underlying Form 4 transaction economics beyond the named filing events.